Mixed cryoglobulinemia and hepatitis C virus. 1994

P Cacoub, and F L Fabiani, and L Musset, and M Perrin, and L Frangeul, and J M Leger, and J M Huraux, and J C Piette, and P Godeau
Department of Internal Medicine, Hôpital La Pitié-Salpêtrière, Paris, France.

BACKGROUND Mixed cryoglobulinemia (MC) is frequently associated with clinical and biological evidence of liver disease and has recently been reported in cases of hepatitis C virus (HCV) infection. The aim of this study was to assess prospectively in a large series of MC patients: (1) the prevalence of HCV markers (anti-HCV antibodies and HCV RNA in serum and cryoprecipitate); (2) the main clinical, biologic and liver histologic features in patients with or without HCV infection. METHODS One hundred fifteen consecutive unselected MC patients were studied: 45% had well-defined underlying diseases ("nonessential" MC). Fifty-five percent with no cause of MC were considered to have "essential" MC and were subjected to in-depth examination. METHODS Patients were considered to have MC if two successive determinations of their serum cryoglobulin level were above 0.05 g/L. Anti-HCV antibodies (Ab) were detected in all patients by second-generation tests (ELISA, RIBA). We also looked for HCV RNA sequences amplified by polymerase chain reaction (PCR) in the sera and cryoprecipitates of 39 patients; HBs antigen, anti-HBs Ab and anti-HBc Ab in all patients; and HBV DNA in 20 sera and 17 cryoprecipitates. Quantitative HCV Ab and RNA studies were performed on whole serum, cryoprecipitates, and supernatants. Clinical features were recorded retrospectively for each patient. Liver biopsies from 23 anti-HCV Ab-positive and 7 anti-HCV Ab-negative patients were examined histologically, with qualitative and quantitative analysis. RESULTS Anti-HCV Ab were found in 47/115 (41%) patients by ELISA and RIBA: 33/63 (52%) essential MC and 14/52 (27%) nonessential MC. Among the 63 essential MC patients, the 33 anti-HCV Ab-positive (Group 1) were compared to the 30 anti-HCV Ab-negative patients (Group 2). Group 1 patients had more cutaneous involvement (Raynaud's phenomenon, purpura, livedo, distal ulcers, or gangrenous changes) (17 versus 5: p = 0.004), higher alanine aminotransferase levels (110 +/- 22 versus 41 +/- 10 IU; p < 0.005), higher serum cryoglobulin levels (0.35 +/- 0.07 versus 0.12 +/- 0.04 g/L; p = 0.01), lower CH50 (28 +/- 3 versus 44 +/- 2 CH50/mL; p = 0.0001) and lower C4 levels (0.20 +/- 0.02 versus 0.29 +/- 0.03 g/L; p < 0.04). The prevalence of HBV serum markers was low in both groups, and HBV DNA was never detected in any of the sera and cryoprecipitates tested. HCV RNA sequences were detected in 10/16 (63%) sera and 12/16 (75%) cryoprecipitates from Group 1 patients, whereas they were not in the sera or cryoprecipitates from 23 Group 2 patients. Using quantitative PCR, HCV RNA in cryoprecipitates was concentrated 20 to 100 times despite the absence of significant anti-HCV Ab concentration in these samples. Histologic examination of liver biopsies revealed a spectrum of lesions ranging from chronic active hepatitis to cirrhosis, but Knodell's score did not differ between the groups. CONCLUSIONS (1) About 50% of the essential MC patients had anti-HCV Ab, and these patients had more severe cryoglobulinemia-associated clinical and biological signs; (2) HCV RNA sequences were found in the large majority of sera and cryoprecipitates from patients with essential MC and anti-HCV Ab and were more concentrated in cryoprecipitates than in supernatants. These results suggest a role for HCV in the pathogenesis of MC and indicate that many cases of essential MC may be secondary to HCV infection and thus nonessential.

UI MeSH Term Description Entries
D008107 Liver Diseases Pathological processes of the LIVER. Liver Dysfunction,Disease, Liver,Diseases, Liver,Dysfunction, Liver,Dysfunctions, Liver,Liver Disease,Liver Dysfunctions
D008111 Liver Function Tests Blood tests that are used to evaluate how well a patient's liver is working and also to help diagnose liver conditions. Function Test, Liver,Function Tests, Liver,Liver Function Test,Test, Liver Function,Tests, Liver Function
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003449 Cryoglobulinemia A condition characterized by the presence of abnormal quantities of CRYOGLOBULINS in the blood. Upon cold exposure, these abnormal proteins precipitate into the microvasculature leading to restricted blood flow in the exposed areas. Cryoglobulinemias
D005260 Female Females
D006508 Hepatitis Antibodies Immunoglobulins raised by any form of viral hepatitis; some of these antibodies are used to diagnose the specific kind of hepatitis. Antibodies, Hepatitis
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

P Cacoub, and F L Fabiani, and L Musset, and M Perrin, and L Frangeul, and J M Leger, and J M Huraux, and J C Piette, and P Godeau
November 1993, Medicina clinica,
P Cacoub, and F L Fabiani, and L Musset, and M Perrin, and L Frangeul, and J M Leger, and J M Huraux, and J C Piette, and P Godeau
January 1991, Clinical and experimental rheumatology,
P Cacoub, and F L Fabiani, and L Musset, and M Perrin, and L Frangeul, and J M Leger, and J M Huraux, and J C Piette, and P Godeau
March 1995, Hospital practice (Office ed.),
P Cacoub, and F L Fabiani, and L Musset, and M Perrin, and L Frangeul, and J M Leger, and J M Huraux, and J C Piette, and P Godeau
March 2007, Minerva gastroenterologica e dietologica,
P Cacoub, and F L Fabiani, and L Musset, and M Perrin, and L Frangeul, and J M Leger, and J M Huraux, and J C Piette, and P Godeau
September 1992, The American journal of gastroenterology,
P Cacoub, and F L Fabiani, and L Musset, and M Perrin, and L Frangeul, and J M Leger, and J M Huraux, and J C Piette, and P Godeau
May 1995, Minerva medica,
P Cacoub, and F L Fabiani, and L Musset, and M Perrin, and L Frangeul, and J M Leger, and J M Huraux, and J C Piette, and P Godeau
January 2012, Clinical & developmental immunology,
P Cacoub, and F L Fabiani, and L Musset, and M Perrin, and L Frangeul, and J M Leger, and J M Huraux, and J C Piette, and P Godeau
May 1994, Medicina clinica,
P Cacoub, and F L Fabiani, and L Musset, and M Perrin, and L Frangeul, and J M Leger, and J M Huraux, and J C Piette, and P Godeau
February 2001, Minerva medica,
P Cacoub, and F L Fabiani, and L Musset, and M Perrin, and L Frangeul, and J M Leger, and J M Huraux, and J C Piette, and P Godeau
January 1994, Journal of the American Academy of Dermatology,
Copied contents to your clipboard!